ORIC News and Press, Oric Pharmaceuticals Inc.

2026-02-24 11:03:49 ET Robert Burns from H.C. Wainwright issued a price target of $25.00 for ORIC on 2026-02-24 15:50:34. The adjusted price target was set to $25.00. At the time of the announcement, ORIC was trading at $13.2661. The overall price target consensus is at ...

Interface Inc. (TILE) is expected to report $0.4 for Q4 2025 Evolent Health Inc Class A (EVH) is expected to report $-0.03 for Q4 2025 MercadoLibre Inc. (MELI) is expected to report $11.77 for Q4 2025 Clean Energy Fuels Corp. (CLNE) is expected to report $-0.1 for Q4 2025 Kiniksa ...

2026-02-24 02:03:47 ET Matthew Biegler from Oppenheimer issued a price target of $15.00 for ORIC on 2026-02-24 05:34:00. The adjusted price target was set to $15.00. At the time of the announcement, ORIC was trading at $11.71. The overall price target consensus is at $22...

2026-02-24 01:15:04 ET Oppenheimer analyst issues OUTPERFORM recommendation for ORIC on February 24, 2026 05:34AM ET. The previous analyst recommendation was Outperform. ORIC was trading at $11.71 at issue of the analyst recommendation. The overall analyst consensus : BU...

2026-02-23 17:06:11 ET More on ORIC Pharmaceuticals ORIC Pharmaceuticals, Inc. (ORIC) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript ORIC Pharmaceuticals: Transition To Late-Stage Development Presents Upside ORIC Pharmaceuticals, Inc. (ORIC) Pr...

Reported rinzimetostat (formerly ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combination with AR inhibitors Presented potential best-in-class enozertinib Phase 1b data ...

2026-02-18 17:14:59 ET ORIC Pharmaceuticals, Inc. (ORIC) Citi's 2026 Virtual Oncology Leadership Summit February 18, 2026 2:30 PM EST... Read the full article on Seeking Alpha For further details see: ORIC Pharmaceuticals, Inc. (ORIC) Presents at Citi's 2026 Virtual Oncology...

Iamgold Corporation (IAG) is expected to report $0.55 for Q4 2025 Bel Fuse Inc (BELFB) is expected to report $1.44 for Q4 2025 Beta Bionics Inc. (BBNX) is expected to report $-0.42 for Q4 2025 TPG RE Finance Trust Inc. (TRTX) is expected to report $0.25 for Q4 2025 CEVA Inc. (CEVA...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The global oncology market is charging toward a massive $668 billion valuation by 2034 [1] , fueled by a structural shift where institutional capital is abandoning discovery-stage...

2026-01-20 13:36:46 ET ... Read the full article on Seeking Alpha For further details see: ORIC Pharmaceuticals: Transition To Late-Stage Development Presents Upside